Deploying patient-facing digital technology and incorporating patient and care partner voice in decentralized clinical trials enable the generation of critical insights. In this talk, TransCelerate will share best practices for deploying digital technologies in DCTs with a focus on understanding patient and care partner voice; they will analyze lessons learned from engaging patients, care partners, sites, sponsors, and regulators in conversations about deploying technology and improving patient experience with DCTs.

Decentralized clinical trials (DCTS) with all of their well-loved patient accommodations ironically pairs with a reduction in the role of sites, previously dedicated to patient care. This session explores the holes created by DCTs with sites’ reduced involvement. We’ll look at patients’ preferred accommodations based on extensive data from patient surveys. Plus, we’ll share case studies from recent DCTs, detailing the emerging education, technology and engagement solutions.

My Trial Community is an insights-driven patient platform that is shaping the Janssen clinical trial experience by: educating Janssen trial participants on what to expect, empowering them with a selection of their own personal data and study results, and engaging them as valued stakeholders through more regular feedback loops. The Janssen team has learned a lot from patients and other stakeholders since initially launching the site in August 2021 and is happy to share key insights.

At AstraZeneca, our values guide everything we do and we are committed to improving the whole patient experience by embedding patient-centric thinking in the medicines, products, and services we develop. For clinical trials, this means that we engage and listen to our patients and sites throughout the clinical development planning, and during this presentation, you will hear more about how we are implementing this approach by setting up processes and by engaging early with key stakeholders.

The biggest challenge in clinical trials that we still need to overcome is that only a small proportion of patients have access to clinical studies as a treatment option. Flexibility ensures that we can meet patients where they are; and where we can maximize their access, convenience, safety, and comfort. Prioritizing patient choice in clinical trials eases the burden on the patient and their caregivers to improve the clinical trial experience.

BMS has been working through a full revamp of our informed consent main template during 2020 and 2021. This was a process that required multiple cross functional stakeholders' engagement & change management in order to develop a more robust template.

As our healthcare system continues to strive for best possible outcomes, we need to recognize that what we’ve always done isn’t working; as an ecosystem, we’ve been adding new tools based on how we want patients to act, yet what we really need is to design our solutions around how people actually behave. Telehealth, digital health tools, and patient portals are expanding initiatives, but we know that technology alone doesn’t drive behavior change as we see patients, providers, consumers, and other stakeholders struggle to begin to engage with the offerings, let alone to continue engaging with them in the long term.

The clinical research industry and innovators from sponsor/vendors/CROs/sites have responded to the Covid pandemic with grit and creativity. One of the outcomes is the continued drive to create and deliver truly patient-centric trials. Our team at Pfizer has learned a lot and challenged ourselves to enable faster, safer and more flexible trials that match patient need and the new reality of reduced timelines. This presentation will share some new work in digital outreach and virtual waiting room for patients.